AU2022247287A1 - Sars-cov-2 mpro inhibitor compounds - Google Patents
Sars-cov-2 mpro inhibitor compounds Download PDFInfo
- Publication number
- AU2022247287A1 AU2022247287A1 AU2022247287A AU2022247287A AU2022247287A1 AU 2022247287 A1 AU2022247287 A1 AU 2022247287A1 AU 2022247287 A AU2022247287 A AU 2022247287A AU 2022247287 A AU2022247287 A AU 2022247287A AU 2022247287 A1 AU2022247287 A1 AU 2022247287A1
- Authority
- AU
- Australia
- Prior art keywords
- dimethyl
- azabicyclo
- cyclopropyl
- hexane
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2104742.8A GB202104742D0 (en) | 2021-04-01 | 2021-04-01 | Sars-Cov-2 MPRO inhibitor compounds |
| GB2104742.8 | 2021-04-01 | ||
| GB2107026.3 | 2021-05-17 | ||
| GBGB2107026.3A GB202107026D0 (en) | 2021-05-17 | 2021-05-17 | SARS-COV-2 MPRO inhibitor compounds |
| PCT/GB2022/050836 WO2022208113A1 (en) | 2021-04-01 | 2022-04-01 | Sars-cov-2 mpro inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022247287A1 true AU2022247287A1 (en) | 2023-11-09 |
Family
ID=81307814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022247287A Abandoned AU2022247287A1 (en) | 2021-04-01 | 2022-04-01 | Sars-cov-2 mpro inhibitor compounds |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240217930A1 (https=) |
| EP (1) | EP4313305A1 (https=) |
| JP (1) | JP2024511881A (https=) |
| KR (1) | KR20240004275A (https=) |
| AU (1) | AU2022247287A1 (https=) |
| CA (1) | CA3213008A1 (https=) |
| WO (1) | WO2022208113A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022306289A1 (en) | 2021-07-09 | 2024-01-18 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| GB202214644D0 (en) * | 2022-10-05 | 2022-11-16 | Heptares Therapeutics Ltd | Sars-cov-2 mpro inhibitors and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1385870T3 (da) * | 2000-07-21 | 2010-07-05 | Schering Corp | Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus |
| US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| EP4146267A1 (en) * | 2020-05-08 | 2023-03-15 | The Board of Trustees of the Leland Stanford Junior University | Protease inhibitors for treatment or prevention of coronavirus disease |
-
2022
- 2022-04-01 CA CA3213008A patent/CA3213008A1/en active Pending
- 2022-04-01 KR KR1020237033735A patent/KR20240004275A/ko active Pending
- 2022-04-01 EP EP22716453.0A patent/EP4313305A1/en active Pending
- 2022-04-01 WO PCT/GB2022/050836 patent/WO2022208113A1/en not_active Ceased
- 2022-04-01 AU AU2022247287A patent/AU2022247287A1/en not_active Abandoned
- 2022-04-01 US US18/553,596 patent/US20240217930A1/en active Pending
- 2022-04-01 JP JP2023560997A patent/JP2024511881A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4313305A1 (en) | 2024-02-07 |
| KR20240004275A (ko) | 2024-01-11 |
| US20240217930A1 (en) | 2024-07-04 |
| JP2024511881A (ja) | 2024-03-15 |
| WO2022208113A1 (en) | 2022-10-06 |
| CA3213008A1 (en) | 2022-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220259145A1 (en) | Sars-cov-2 main protease inhibitors | |
| RU2607045C2 (ru) | Бензиламиновые производные как ингибиторы калликреина плазмы | |
| AU2022247287A1 (en) | Sars-cov-2 mpro inhibitor compounds | |
| EP4263502B1 (en) | Sars-cov-2 mpro inhibitor compounds | |
| JP2010509195A (ja) | トランスグルタミナーゼ阻害剤としてのマイケル・システム | |
| US20090203629A1 (en) | Inhibitors of cathepsin b | |
| ES2308181T3 (es) | Inhibidores de proteasa. | |
| US12060333B2 (en) | Aminocarbamoyl compounds for the treatment of viral infections | |
| WO2017151587A1 (en) | Aza-peptide aldehydes and ketones | |
| US20230099089A1 (en) | Antiviral substances with a wide spectrum of activity | |
| CN117858867A (zh) | Sars-cov-2 mpro抑制剂化合物 | |
| WO2024089159A1 (en) | Main protease inhibitors | |
| EP4587433A1 (en) | 3-(1h-indole-2-carbonyl)-6,6-dimethyl-n-((s)-1-oxo-3-((s)-2-oxopyrrolidin-3-yl)p ropan-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide derivatives as mpro inhibitors for the treatment of coronavirus infections | |
| HK40094156B (en) | Sars-cov-2 mpro inhibitor compounds | |
| HK40094156A (en) | Sars-cov-2 mpro inhibitor compounds | |
| CN117136178A (zh) | SARS-COV-2 Mpro抑制剂化合物 | |
| WO2025253129A1 (en) | Sars-cov-2 mpro inhibitors and uses thereof | |
| CA2569729C (en) | Peptidomimetic inhibitors of retroviral proteases and their use as antivirals | |
| NO305085B1 (no) | HIV-proteaseinhibitorer, farmas°ytiske preparater som omfatter slike, samt fremgangsmÕte for in vitro inhibering av HIV-virusreplikasjon | |
| CA2267657A1 (en) | Hydroxyphenyl derivatives with hiv integrase inhibitory properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: NXERA PHARMA UK LIMITED Free format text: FORMER NAME(S): HEPTARES THERAPEUTICS LIMITED |
|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |